{"url_path":"/sec/neo/8-k/2026-08-11/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1077183/0001628280-26-055697-index.html","accession_number":"0001628280-26-055697","cik":"0001077183","ticker":"NEO","issuer_name":"NEOGENOMICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1077183/0001628280-26-055697-index.html","primary_entity_key":"0001077183","primary_entity_name":"NEOGENOMICS INC"},"word_count":138,"has_tables":true,"body_markdown":"Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\nOn August 11, 2026, NeoGenomics, Inc. (the “Company”) announced that Alicia Olivo, EVP, General Counsel & Business Development, would transition from her role with the Company and cease to serve as General Counsel effective as of September 21, 2026. Ms. Olivo will remain an employee of the Company until October 2, 2026 for transitional purposes. In connection with her departure from the Company, Ms. Olivo will be eligible to receive separation payments and benefits consistent with the terms of Section 5(b) of Ms. Olivo’s employment agreement, the form of which was incorporated by reference in the Company’s Form 10-K for the fiscal year ended December 31, 2025, as filed with the Securities and Exchange Commission on February 17, 2026."}